Technology Review - Published By MIT
Log in to My.TechnologyReview.com | Register
Advertisement
[1] 2 Next »

Monday, April 09, 2007

DNA Factories

Cheaply churning out made-to-order DNA could revolutionize molecular biology.

By Emily Singer

smaller text tool iconmedium text tool iconlarger text tool icon
Credit: Technology Review

Installing one of those prefab, snap-together wood-flooring kits is a lot easier than shaping and sanding rough planks. Adapting a similar construction strategy, a biotech startup called Codon Devices, based in Cambridge, MA, aims to streamline genetic engineering. It makes made-to-order DNA strands, freeing scientists from the finicky work it takes to put together a complicated piece of DNA the old-fashioned way.

That capability could soon change the face of molecular biology. As it becomes cheaper and cheaper to create large chunks of genetic material from scratch, scientists will be able to make ever more complex biological creations. "In the next few years, we'll probably see people engineering cells to do drug delivery or creating cellular sensors," says George Church, a professor of genetics at Harvard and one of Codon's founders. "Maybe even cells that make inorganic objects of interest, like nanostructures."

Codon was founded in 2005 just as the fledgling field of synthetic biology--the quest to design and build new life forms that can perform useful functions--was beginning to take off. The ability to make complex genetic constructs is a cornerstone of the field, allowing scientists to use chunks of DNA to design novel biological parts, which can then be inserted into bacteria or other cells. (See "Synthetic Biology on Display.")

While DNA synthesis is still too expensive to replace more-traditional molecular-biology methods on a broad scale, experts say that the DNA-synthesis market is about to boom, much as the DNA-sequencing market has in the past few years. As sequencing costs plummeted, the number of sequencing projects surged, with record numbers of genomes--even entire microbial communities--being sequenced. "As large companies begin to adopt this technology, the volumes of DNA synthesis will explode," says John Danner, president and chief executive officer of Codon. "When that happens, thousands of scientists will think about this when they go to sleep at night, and that will change how biotech is done."

Last summer, the company created what it believes was the biggest piece of man-made DNA, a 35,000 base-pair strand incorporating several genes needed to synthesize a pharmaceutical compound. The DNA was made for Microbia, another Cambridge-based biotech, which is creating microbes to manufacture specialty chemicals. But the potential applications are broad, spanning pharmaceuticals, energy, and agriculture.

Synthetic biologists are excited about the prospects, but they're still waiting for a decrease in price to the point that they can afford to do the experiments they want to do. "Cost is the critical component to making this technology work," says Chris Voigt, a synthetic biologist at the University of San Francisco. "Right now, we can design one construct that costs a fortune to make. But we want to be able to order different components put together in different ways so we can study the critical factor in putting them together."

[1] 2 Next »

Comments

  • mother nature
    islandinthenet on 04/09/2007 at 6:59 AM
    Posts:
    3
    "Since nature hasn't always come up with the most effective proteins.."

    What do you mean by that?  I think the sentence should read, "Since nature hasn't always come up with the most effective proteins [from a business perspective]".

    I don't think mother nature has economic capitalism in mind when she design a living organism.
    Rate this comment: 12345
    • Re: mother nature
      ac on 04/09/2007 at 1:03 PM
      Posts:
      1
      Mother nature had natural selection in mind when she designed living organisms, and natural selection works hand-in-hand with the forces of supply and demand.
      Rate this comment: 12345
  • forced to supply
    phoenix on 04/09/2007 at 8:05 PM
    Posts:
    80
    Avg Rating:
    2/5
    Sorry, but I'm afraid that you can't equate the term Mother Nature with economic/sociological functions. There is absolutely no corelation. The processes you hoped to describe respond to much more subtle inferences.
    Rate this comment: 12345
  • synthetic biopharmaceuticals
    duchmol on 04/10/2007 at 11:51 AM
    Posts:
    1
    I think this has great potential in the biopharmaceutical world, namely in the gene transfer products field. The point is that a chemically synthesized biopharmaceutical will always be easier to get accepted by regulators when compared to a biologically-made one. And easier means shorter time to market, less uncertainty, i.e. more $$. Think about a purely synthetic genome of a viral vector coding for an immunogen. And they would be true generics for gene transfer biopharmaceuticals, not just biosimilars. Chemically synthetised biopharmaceuticals have the potential to be more profitable than the "natural" ones, think about it
    Rate this comment: 12345
Advertisement

Current Issue

Technology Review July/August 2008
The Business of Social Networks
The future of the Web is social. But can social-networking sites ever make money?
•  Subscribe
Save 41%
•  Table of Contents
•  MIT News

Magazine Services

Career Resources

MIT Technology Insider

Stories and breaking news from inside MIT about the latest research, innovations, and startups--in a convenient monthly e-newsletter. Subscribe today
Advertisement
Advertisement
Advertisement
Advertisement
TECHNOLOGY RESOURCES
Advertisement
MIT Massachusetts Institute of Technology